{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T02:43:00Z","timestamp":1772246580218,"version":"3.50.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>In these times of COVID-19 pandemic, concern has been raised about the potential effects of SARS-CoV-2 infection on immunocompromised patients, particularly on those receiving B-cell depleting agents and having therefore a severely depressed humoral response. Convalescent plasma can be a therapeutic option for these patients. Understanding the underlying mechanisms of convalescent plasma is crucial to optimize such therapeutic approach. Here, we describe a COVID-19 patient who was deeply immunosuppressed following rituximab (anti-CD20 monoclonal antibody) and concomitant chemotherapy for chronic lymphoid leukemia. His long-term severe T and B cell lymphopenia allowed to evaluate the treatment effects of convalescent plasma. Therapeutic outcome was monitored at the clinical, biological and radiological level. Moreover, anti-SARS-CoV-2 antibody titers (IgM, IgG and IgA) and neutralizing activity were assessed over time before and after plasma transfusions, alongside to SARS-CoV-2 RNA quantification and virus isolation from the upper respiratory tract. Already after the first cycle of plasma transfusion, the patient experienced rapid\u00a0improvement of pneumonia, inflammation and blood cell counts, which may be related to the\u00a0immunomodulatory properties of plasma.\u00a0Subsequently, the cumulative increase in anti-SARS-CoV-2 neutralizing antibodies due to the three additional plasma transfusions was associated with progressive and finally complete viral clearance, resulting in full clinical recovery. In this case-report, administration of convalescent plasma revealed a stepwise effect with an initial and rapid anti-inflammatory activity followed by the progressive SARS-CoV-2 clearance. These data have potential implications for a more extended use of convalescent plasma and future monoclonal antibodies in the treatment of immunosuppressed COVID-19 patients.<\/jats:p>","DOI":"10.3389\/fimmu.2021.613502","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T01:50:31Z","timestamp":1618969831000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery"],"prefix":"10.3389","volume":"12","author":[{"given":"Aurelia","family":"Zimmerli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Monti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Fenwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Eckerle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Beigelman-Aubry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Pellaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Jaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian-Marco","family":"Stamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Infanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidrun","family":"Andreu-Ullrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daphn\u00e9","family":"Germann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Mean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Vollenweider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael","family":"Stadelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maura","family":"Prella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Comte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Guery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Gachoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Rufer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16896","article-title":"Persisting SARS-CoV-2 Viraemia After Rituximab Therapy: Two Cases With Fatal Outcome and A Review of the Literature","volume":"190","author":"Tepasse","year":"2020","journal-title":"Br J Haematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003170","article-title":"Outcomes of Patients With Hematologic Malignancies and COVID-19: A Report from the ASH Research Collaborative Data Hub","volume":"4","author":"Wood","year":"2020","journal-title":"Blood Adv"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers7010305","article-title":"Immunreconstitution and Infectious Complications After Rituximab Treatment in Children and Adolescents: What Do We Know and What Can We Learn from Adults","volume":"7","author":"Worch","year":"2015","journal-title":"Cancers (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2017-0178","article-title":"Consequences of B-cell-depleting Therapy: Hypogammaglobulinemia and Impaired B-cell Reconstitution","volume":"10","author":"Sacco","year":"2018","journal-title":"Immunotherapy"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138003","article-title":"The Convalescent Sera Option for Containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"J Clin Invest"},{"key":"B6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-Analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12926","article-title":"Collecting and Evaluating Convalescent Plasma for COVID-19 Treatment: Why and How","volume":"115","author":"Tiberghien","year":"2020","journal-title":"Vox Sang"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12607","article-title":"Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial","volume":"324","author":"Li","year":"2020","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033700","article-title":"Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults","volume":"384","author":"Libster","year":"2021","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031893","article-title":"Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19","volume":"384","author":"Joyner","year":"2021","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102554","article-title":"Convalescent Plasma in Covid-19: Possible Mechanisms of Action","volume":"19","author":"Rojas","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/femspd\/ftaa061","article-title":"Comparison of SARS-CoV-2 RT-PCR on a High-Throughput Molecular Diagnostic Platform and the Cobas SARS-CoV-2 Test for the Diagnostic of COVID-19 on Various Clinical Samples","volume":"78","author":"Opota","year":"2020","journal-title":"Pathog Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2020.08.004","article-title":"Viral Load of SARS-CoV-2 Across Patients and Compared to Other Respiratory Viruses","volume":"22","author":"Jacot","year":"2020","journal-title":"Microbes Infect"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-020-06801-0","article-title":"Chest CT Manifestations of New Coronavirus Disease 2019 (COVID-19): A Pictorial Review","volume":"30","author":"Ye","year":"2020","journal-title":"Eur Radiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2807\/1560-7917.ES.2020.25.28.2001260","article-title":"Convalescent Plasma Treatment for SARS-CoV-2 Infection: Analysis of the First 436 Donors in England, 22 April to 12 May 2020","volume":"25","author":"Harvala","year":"2020","journal-title":"Euro Surveill"},{"key":"B16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jim.2017.11.008","article-title":"Comparison of CyTOF Assays Across Sites: Results of a Six-Center Pilot Study","volume":"453","author":"Leipold","year":"2018","journal-title":"J Immunol Methods"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody Responses to SARS-CoV-2 in Patients with COVID-19","volume":"26","author":"Long","year":"2020","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/JVI.01828-20","article-title":"Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies","volume":"95","author":"Fenwick","year":"2021","journal-title":"J Virol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3201\/eid2610.202403","article-title":"Culture-Competent SARS-CoV-2 in Nasopharynx of Symptomatic Neonates, Children, and Adolescents","volume":"26","author":"L\u2019Huillier","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous Immunoglobulin in Neurology\u2013Mode of Action and Clinical Efficacy","volume":"11","author":"Lunemann","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008423","article-title":"Convalescent Plasma Therapy for B-cell-depleted Patients With Protracted COVID-19","volume":"136","author":"Hueso","year":"2020","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138745","article-title":"Deployment of Convalescent Plasma for the Prevention and Treatment of COVID-19","volume":"130","author":"Bloch","year":"2020","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent Neutralizing Antibodies Against Multiple Epitopes on SARS-CoV-2 Spike","volume":"584","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100164","article-title":"Convalescent Plasma-Mediated Resolution of COVID-19 in a Patient with Humoral Immunodeficiency","volume":"2","author":"Honjo","year":"2021","journal-title":"Cell Rep Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd6160","article-title":"SARS-CoV-2 T Cell Immunity: Specificity, Function, Durability, and Role in Protection","volume":"5","author":"Altmann","year":"2020","journal-title":"Sci Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jaci.2020.04.013","article-title":"A Possible Role for B Cells in COVID-19? Lesson from Patients With Agammaglobulinemia","volume":"146","author":"Quinti","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.596761","article-title":"Case Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19","volume":"11","author":"Van Damme","year":"2020","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3457","article-title":"Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients","volume":"9","author":"Tremblay","year":"2020","journal-title":"Cancer Med"},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.21203\/rs.3.rs-76799\/v1","article-title":"Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery","volume-title":"Res Square.","author":"Zimmerli","year":""}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.613502\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,2]],"date-time":"2021-05-02T00:39:02Z","timestamp":1619915942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.613502\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,21]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2021.613502"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.613502","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-76799\/v1","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,21]]},"article-number":"613502"}}